Brokerages Set LeMaitre Vascular, Inc. (NASDAQ:LMAT) Target Price at $94.57

LeMaitre Vascular, Inc. (NASDAQ:LMAT) has earned an average rating of “Moderate Buy” from the nine ratings firms that are presently covering the stock, MarketBeat reports. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $94.57.

Several research analysts have recently issued reports on LMAT shares. Oppenheimer reiterated an “outperform” rating and issued a $93.00 price objective (up from $90.00) on shares of LeMaitre Vascular in a report on Friday, November 1st. JMP Securities lifted their price target on LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a research report on Tuesday, August 20th. StockNews.com cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. Cantor Fitzgerald assumed coverage on shares of LeMaitre Vascular in a research report on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 price target on the stock. Finally, Barrington Research upped their price target on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a report on Friday, November 1st.

Insiders Place Their Bets

In other news, Director Bridget A. Ross sold 3,750 shares of the stock in a transaction on Friday, November 15th. The stock was sold at an average price of $101.47, for a total value of $380,512.50. Following the completion of the sale, the director now owns 2,278 shares in the company, valued at $231,148.66. This represents a 62.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 10.79% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. CANADA LIFE ASSURANCE Co grew its stake in LeMaitre Vascular by 44.7% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 22,252 shares of the medical instruments supplier’s stock valued at $1,472,000 after acquiring an additional 6,875 shares in the last quarter. Sequoia Financial Advisors LLC acquired a new position in LeMaitre Vascular in the 2nd quarter valued at approximately $1,010,000. Janus Henderson Group PLC lifted its position in LeMaitre Vascular by 554.7% in the 1st quarter. Janus Henderson Group PLC now owns 55,730 shares of the medical instruments supplier’s stock worth $3,697,000 after buying an additional 47,218 shares in the last quarter. Harbor Capital Advisors Inc. boosted its stake in shares of LeMaitre Vascular by 240.2% during the 2nd quarter. Harbor Capital Advisors Inc. now owns 11,296 shares of the medical instruments supplier’s stock valued at $929,000 after buying an additional 7,976 shares during the period. Finally, Townsquare Capital LLC grew its holdings in shares of LeMaitre Vascular by 38.0% during the 3rd quarter. Townsquare Capital LLC now owns 47,953 shares of the medical instruments supplier’s stock valued at $4,454,000 after acquiring an additional 13,210 shares in the last quarter. 84.64% of the stock is owned by institutional investors and hedge funds.

LeMaitre Vascular Stock Up 1.1 %

Shares of LMAT stock opened at $106.99 on Thursday. LeMaitre Vascular has a 52-week low of $51.70 and a 52-week high of $109.58. The stock’s 50-day moving average price is $95.52 and its 200 day moving average price is $87.96. The stock has a market capitalization of $2.41 billion, a PE ratio of 58.46, a price-to-earnings-growth ratio of 2.59 and a beta of 0.89.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share for the quarter, beating analysts’ consensus estimates of $0.44 by $0.05. The business had revenue of $54.82 million for the quarter, compared to analysts’ expectations of $53.50 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The company’s revenue was up 15.6% on a year-over-year basis. During the same period in the previous year, the business earned $0.33 earnings per share. Analysts expect that LeMaitre Vascular will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 5th. Shareholders of record on Thursday, November 21st will be issued a dividend of $0.16 per share. The ex-dividend date of this dividend is Thursday, November 21st. This represents a $0.64 annualized dividend and a yield of 0.60%. LeMaitre Vascular’s payout ratio is presently 34.97%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.